Literature DB >> 24987918

Maximum standardized uptake value of fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in ovarian clear cell adenocarcinoma.

Haruhisa Konishi1, Kazuhiro Takehara, Atsumi Kojima, Shinichi Okame, Yasuko Yamamoto, Yuko Shiroyama, Takashi Yokoyama, Takayoshi Nogawa, Yoshifumi Sugawara.   

Abstract

BACKGROUND: Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) is useful for diagnosing malignant tumors. Intracellular FDG uptake is measured as the standardized uptake value (SUV), which differs depending on tumor characteristics. This study investigated differences in maximum SUV (SUVmax) according to histologic type in ovarian epithelial cancer and the relationship of SUVmax with prognosis.
METHODS: This study included 80 patients with ovarian epithelial cancer based on histopathologic findings at surgery and who had undergone PET/CT before treatment. Maximum SUV on PET/CT of primary lesions and histopathology were compared based on histologic type, and the prognosis associated with different SUVmax was evaluated.
RESULTS: Clinical tumor stage was I in 35 patients, II in 8, III in 25, and IV in 12. Histologic type was serous adenocarcinoma (AC) in 33 patients, clear cell AC in 27, endometrioid AC in 15, and mucinous AC in 5. Median SUVmax was lower in mucinous AC (2.76) and clear cell AC (4.9) than in serous AC (11.4) or endometrioid AC (11.4). Overall, median SUVmax was lower in clinical stage I (5.37) than in clinical stage ≥II (10.3). However, in both clear cell AC and endometrioid AC, when histologic evaluation was possible, no difference was seen between stage I and stage ≥II. Moreover, in clear cell AC, the 5-year survival rate was significantly higher in the low-SUVmax group (100%) than in the high-SUVmax group (43.0%, P = 0.009).
CONCLUSIONS: Maximum SUV on preoperative FDG-PET/CT in ovarian epithelial cancer differs according to histologic type. In clear cell AC, SUVmax may represent a prognostic factor.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24987918     DOI: 10.1097/IGC.0000000000000180

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  11 in total

1.  The usefulness of 18F-FDG-PET/CT in discriminating benign from malignant ovarian teratomas.

Authors:  Takanori Yokoyama; Kazuhiro Takehara; Yasuko Yamamoto; Shinichi Okame; Yuko Shiroyama; Takashi Yokoyama; Takayoshi Nogawa; Yosifumi Sugawara
Journal:  Int J Clin Oncol       Date:  2015-02-15       Impact factor: 3.402

2.  18F-FDG PET/CT can predict chemosensitivity and proliferation of epithelial ovarian cancer via SUVmax value.

Authors:  Shuai Liu; Zheng Feng; Hao Wen; Zhaoxia Jiang; Herong Pan; Yu Deng; Lei Zhang; Xingzhu Ju; Xiaojun Chen; Xiaohua Wu
Journal:  Jpn J Radiol       Date:  2018-06-25       Impact factor: 2.374

3.  Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.

Authors:  Federico Caobelli; Pierpaolo Alongi; Laura Evangelista; Maria Picchio; Giorgio Saladini; Marco Rensi; Onelio Geatti; Angelo Castello; Iashar Laghai; Cristina E Popescu; Carlotta Dolci; Cinzia Crivellaro; Silvia Seghezzi; Margarita Kirienko; Vincenzo De Biasi; Fabrizio Cocciolillo; Natale Quartuccio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-18       Impact factor: 9.236

4.  Evaluation of patients with advanced epithelial ovarian cancer before primary treatment: correlation between tumour burden assessed by [18F]FDG PET/CT volumetric parameters and tumour markers HE4 and CA125.

Authors:  Ariel Glickman; Pilar Paredes; Núria Carreras-Diéguez; Aida Niñerola-Baizán; Lydia Gaba; Jaume Pahisa; Pere Fusté; Marta Del Pino; Berta Díaz-Feijóo; Eduardo González-Bosquet; Núria Agustí; Nuria Sánchez-Izquierdo; David Fuster; Andrés Perissinotti; Inmaculada Romero; Esther Fernández-Galán; Josep Lluís Carrasco; Blanca Gil-Ibáñez; Aureli Torné
Journal:  Eur Radiol       Date:  2021-09-29       Impact factor: 7.034

Review 5.  Ovarian clear cell carcinoma meets metabolism; HNF-1β confers survival benefits through the Warburg effect and ROS reduction.

Authors:  Masaki Mandai; Yasuaki Amano; Ken Yamaguchi; Noriomi Matsumura; Tsukasa Baba; Ikuo Konishi
Journal:  Oncotarget       Date:  2015-10-13

6.  Metabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum-based adjuvant chemotherapy.

Authors:  Makoto Yamamoto; Tetsuya Tsujikawa; Yuko Fujita; Yoko Chino; Tetsuji Kurokawa; Yasushi Kiyono; Hidehiko Okazawa; Yoshio Yoshida
Journal:  Cancer Sci       Date:  2016-02-23       Impact factor: 6.716

7.  Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.

Authors:  Azahara Palomar Muñoz; José Manuel Cordero García; Mª Del Prado Talavera Rubio; Ana Mª García Vicente; Francisco José Pena Pardo; Germán Andrés Jiménez Londoño; Ángel Soriano Castrejón; Enrique Aranda Aguilar
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

8.  Diagnostic accuracy of 18F-FDG PET/CT scan for peritoneal metastases in advanced ovarian cancer.

Authors:  Zheng Feng; Shuai Liu; Xingzhu Ju; Xiaojun Chen; Ruimin Li; Rui Bi; Xiaohua Wu
Journal:  Quant Imaging Med Surg       Date:  2021-08

9.  Correlation between histological grade and positron emission tomography parameters in cervical carcinoma.

Authors:  Vanessa Mocciaro; Paolo Scollo; Alessandro Stefano; Stefania Gieri; Giorgio Russo; Giuseppe Scibilia; Sebastiano Cosentino; Gabriella Murè; Sara Baldari; Maria Gabriella Sabini; Filippo Fraggetta; Maria Carla Gilardi; Massimo Ippolito
Journal:  Oncol Lett       Date:  2016-06-23       Impact factor: 2.967

10.  The maximum standardized uptake value and extent of peritoneal involvement may predict the prognosis of patients with recurrent ovarian cancer after primary treatment: A retrospective clinical study.

Authors:  Yuanyuan Jiang; Guozhu Hou; Fengyu Wu; Zhaohui Zhu; Wei Zhang; Wuying Cheng
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.